Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.

Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.

SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.

Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.

Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.

NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.

Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.

Ionis Pharmaceuticals reported successful recruitment completion and encouraging early outcomes from the first phase of the HALOS Phase 1/2a trial for ION582 (BIIB121) targeting Angelman syndrome.

Initial Participant Receives Treatment in Phase III ProstACT GLOBAL Trial for Antibody-driven Prostate Cancer Candidate Therapy, TLX591.

Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran, a potential RNAi treatment, designed for addressing hypertension in individuals with significant cardiovascular risk.

Abelacimab 150 mg, a unique Factor XI/XIa inhibitor from Anthos Therapeutics, showcased a 67% decline in significant or notably relevant non-major bleeding versus Rivaroxaban in atrial fibrillation patients.

Novartis research suggests that remibrutinib, an oral medication, can effectively ease symptoms of chronic spontaneous urticaria as early as the second week of treatment.